Targeting Mitochondria as a Therapeutic Approach for Parkinson’s Disease

被引：0
作者：
Maryam Abrishamdar
Maryam Sadat Jalali
Yaghoob Farbood
机构：
[1] Ahvaz Jundishapur University of Medical Sciences,Department of Physiology, Persian Gulf Physiology Research Center, Medical Basic Sciences Research Institute
[2] Ahvaz Jundishapur University of Medical Sciences,Department of Physiology, Medicine Faculty, Persian Gulf Physiology Research Center, Medical Basic Sciences Research Institute
来源：
Cellular and Molecular Neurobiology | 2023年 / 43卷
关键词：
Parkinson’s disease; Mitochondrial dysfunction; Neurodegeneration;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Neurodegeneration is among the most critical challenges that involve modern societies and annually influences millions of patients worldwide. While the pathophysiology of Parkinson’s disease (PD) is complicated, the role of mitochondrial is demonstrated. The in vitro and in vivo models and genome-wide association studies in human cases proved that specific genes, including PINK1, Parkin, DJ-1, SNCA, and LRRK2, linked mitochondrial dysfunction with PD. Also, mitochondrial DNA (mtDNA) plays an essential role in the pathophysiology of PD. Targeting mitochondria as a therapeutic approach to inhibit or slow down PD formation and progression seems to be an exciting issue. The current review summarized known mutations associated with both mitochondrial dysfunction and PD. The significance of mtDNA in Parkinson's disease pathogenesis and potential PD therapeutic approaches targeting mitochondrial dysfunction was then discussed.
引用
收藏
页码：1499 / 1518
页数：19
相关论文
共 1895 条
[1]  
Abdelkader NF(2016)Ursodeoxycholic acid ameliorates apoptotic cascade in the rotenone model of parkinson’s disease: modulation of mitochondrial perturbations Mol Neurobiol 53 810-817
[2]  
Safar MM(2021)Curcumin pre-treatment may protect against mitochondrial damage in LRRK2-mutant Parkinson's disease and healthy control fibroblasts Biochem Biophys Rep 27 2798-2811
[3]  
Salem HA(2015)PINK1 kinase catalytic activity is regulated by phosphorylation on serines 228 and 402 J Biol Chem 290 169-202
[4]  
Abrahams S(2020)Enhancing mitophagy as a therapeutic approach for neurodegenerative diseases Int Rev Neurobiol 155 91-113
[5]  
Miller HC(2018)Current perspective of mitochondrial biology in parkinson’s disease Neurochem Int 117 807-818
[6]  
Lombard C(2007)Bioavailability of curcumin: problems and promises Mol Pharm 4 457-465
[7]  
van der Westhuizen FH(1981)Sequence and organization of the human mitochondrial genome Nature 290 701-713
[8]  
Bardien S(2005)Effects of creatine treatment on the survival of dopaminergic neurons in cultured fetal ventral mesencephalic tissue Neuroscience 133 214-226
[9]  
Aerts L(2020)Ferulic acid reinstates mitochondrial dynamics through PGC1α expression modulation in 6-hydroxydopamine lesioned rats Phytotherapy Research : PTR 34 117-120
[10]  
Craessaerts K(2010)Variations of the CAG trinucleotide repeat in DNA polymerase γ (POLG1) is associated with parkinson’s disease in Sweden Neurosci Lett 485 1423-1431
12345678910